3 Stocks Estimated To Be Trading At Discounts Of Up To 49.9%

As global markets continue to navigate the complexities of rising inflation and shifting trade policies, U.S. stock indexes are climbing toward record highs, with growth stocks outperforming value shares. In this environment, identifying undervalued stocks can offer potential opportunities for investors seeking to capitalize on market inefficiencies and the broader economic landscape.

Top 10 Undervalued Stocks Based On Cash Flows

Name	Current Price	Fair Value (Est)	Discount (Est)
Ningbo Sanxing Medical ElectricLtd (SHSE:601567)	CN¥26.41	CN¥51.88	49.1%
Vimi Fasteners (BIT:VIM)	€0.97	€1.91	49.2%
Hibino (TSE:2469)	¥2770.00	¥5502.58	49.7%
Shanghai Haohai Biological Technology (SEHK:6826)	HK$26.30	HK$52.47	49.9%
Power Wind Health Industry (TWSE:8462)	NT$110.50	NT$220.43	49.9%
América Móvil. de (BMV:AMX B)	MX$15.07	MX$29.71	49.3%
Accent Group (ASX:AX1)	A$2.11	A$4.19	49.6%
Saigon Thuong Tin Commercial Bank (HOSE:STB)	₫38750.00	₫76325.14	49.2%
Com2uS (KOSDAQ:A078340)	₩48250.00	₩96043.58	49.8%
Shenzhen Anche Technologies (SZSE:300572)	CN¥18.75	CN¥36.88	49.2%

Click here to see the full list of 906 stocks from our Undervalued Stocks Based On Cash Flows screener.

Here we highlight a subset of our preferred stocks from the screener.

Figeac Aero Société Anonyme (ENXTPA:FGA)

Overview: Figeac Aero Société Anonyme manufactures, supplies, and sells equipment and sub-assemblies for the aeronautics sector in France, with a market cap of €345.57 million.

Operations: The company's revenue is primarily derived from Aerostructures & Aeromotors, which account for €382.40 million, complemented by Diversification Activities contributing €33.50 million.

Estimated Discount To Fair Value: 37.2%

Figeac Aero Société Anonyme is trading at €8.44, significantly below its estimated fair value of €13.43, highlighting potential undervaluation based on cash flows. Recent earnings showed sales growth to €200 million, with a reduced net loss of €4.4 million. The company secured a $5 million contract with GKN Aerospace, leveraging existing capacity without significant investment needs. Earnings are forecast to grow substantially and the company is expected to become profitable within three years.

• Our expertly prepared growth report on Figeac Aero Société Anonyme implies its future financial outlook may be stronger than recent results.
• Click here and access our complete balance sheet health report to understand the dynamics of Figeac Aero Société Anonyme.

Doosan Fuel Cell (KOSE:A336260)

Overview: Doosan Fuel Cell Co., Ltd. develops and distributes power generation fuel cells in South Korea, with a market cap of approximately ₩1.09 trillion.

Operations: The company's revenue is primarily derived from its Electric Equipment segment, which generated approximately ₩260.89 billion.

Estimated Discount To Fair Value: 48.2%

Doosan Fuel Cell Co., Ltd. is trading at ₩16,660, which is considerably below its estimated fair value of ₩32,165.92, suggesting it may be undervalued based on cash flows. Earnings are forecast to grow 83.8% annually and the company is expected to become profitable within three years with revenue growth projected at 19.2% per year, outpacing the Korean market average of 9%. However, interest payments are not well covered by earnings and return on equity remains low at 4.2%.

• In light of our recent growth report, it seems possible that Doosan Fuel Cell's financial performance will exceed current levels.
• Unlock comprehensive insights into our analysis of Doosan Fuel Cell stock in this financial health report.

Shanghai Haohai Biological Technology (SEHK:6826)

Overview: Shanghai Haohai Biological Technology Co., Ltd. operates in the biopharmaceutical industry, focusing on the development and production of biological materials and medical devices, with a market cap of approximately HK$13.06 billion.

Operations: Shanghai Haohai Biological Technology Co., Ltd. generates revenue through its biopharmaceutical operations, concentrating on biological materials and medical devices.

Estimated Discount To Fair Value: 49.9%

Shanghai Haohai Biological Technology is trading at HK$26.3, significantly below its estimated fair value of HK$52.47, highlighting potential undervaluation based on cash flows. Earnings are projected to grow 20.13% annually, surpassing the Hong Kong market's growth rate of 11.7%. Recent earnings show modest increases in sales and net income, while a share buyback program has been completed for CNY 30.58 million, potentially enhancing shareholder value despite an unstable dividend history and low forecasted return on equity at 9.9%.

• Our earnings growth report unveils the potential for significant increases in Shanghai Haohai Biological Technology's future results.
• Click to explore a detailed breakdown of our findings in Shanghai Haohai Biological Technology's balance sheet health report.

Next Steps

• Investigate our full lineup of 906 Undervalued Stocks Based On Cash Flows right here.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com